Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is an important negative regulator of cell growth and a tumor suppressor. Its growth-attenuating activity is based on the dephosphorylation of phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ), an essential second messenger for the phosphoinositide 3-kinase/Akt signaling pathway. This activity may require localization of PTEN to cytoplasmic membranes. Yet PTEN can also localize to the cell nucleus where its functions remain unclear. Here we present data that define a short sequence in the N-terminal region of PTEN required for cytoplasmic localization. We will refer to this sequence as cytoplasmic localization signal (CLS). It could function as a noncanonical signal for nuclear export or as a cytoplasmic retention signal of PTEN. Mutations within the CLS induce nuclear localization and impair growth suppressive activities of PTEN while preserving lipid phosphatase activity. We propose that nuclear localization of PTEN is not compatible with plasma membrane-targeted growth suppressive functions of PTEN.
Introduction
The tumor suppressor gene phosphatase and tensin homolog deleted on chromosome 10 (PTEN) encodes a 403-amino-acid protein that has lipid and protein phosphatase activity Li and Sun, 1997; Myers et al., 1997; Steck et al., 1997) . It antagonizes the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway by dephosphorylating membrane-localized phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ) Dixon, 1998, 1999) . Functional inactivation of PTEN results in constitutive upregulation of PI3K/Akt signaling, which promotes cell cycle progression, cellular survival, enhanced protein synthesis, cell migration and tumor-induced angiogenesis (Li and Sun, 1998; Sun et al., 1999; Vogt, 2001; Wen et al., 2001; Su et al., 2003; Leslie et al., 2005) . PTEN contains an N-terminal phosphatidylinositol 4,5-bisphosphate (PIP 2 ) binding motif followed by the phosphatase domain (PTP), a Ca 2 þ -independent C2 domain and a C-terminal tail .
PTEN is primarily cytoplasmic; binding of PTEN to the plasma membrane is mediated by a combination of cationic patches located in the N-terminal PIP 2 binding motif (R11/K13/R14/R15) and in the phosphatase domain (R161/K163/K164) along with contributions by the C2 domain (Das et al., 2003; Leslie and Downes, 2004) . PTEN can also be detected in the nucleus, but the determinants for nuclear-cytoplasmic shuttling are not well understood (Lian and Di Cristofano, 2005) . PTEN lacks a classical nuclear localization signal (NLS). However, a recent study has identified NLS-like sequences in PTEN that mediate nuclear entry by the major vault protein (MVP) . Recent studies suggest that nuclear PTEN mediates growth suppression independent of downregulating Akt, whereas cytoplasmic PTEN mediates apoptosis Liu et al., 2005) . These studies document the importance of cellular localization in the regulation of PTEN function.
We have examined a highly conserved region of PTEN situated near the N-terminal PIP 2 binding motif (amino acids 19-25, DGFDLDL). Germ line and somatic mutations within this region indicate that it plays a critical role in the tumor suppressor function of PTEN (Bonneau and Longy, 2000) . We generated the amino acid substitution mutant F21A and found that it is localized predominantly in the cell nucleus. Examination of other, naturally occurring mutants within this region indicates that this region is required for cytoplasmic localization; hence, we refer to this region as a cytoplasmic localization signal (CLS). Mutations within the CLS that lead to nuclear localization also result in a loss of PTEN growth suppressing activity while preserving lipid phosphatase activity. Our data define elements within the PTEN sequence that determine cellular localization and suggest that cytoplasmic/ plasma membrane localization is essential for growth regulatory activities of PTEN.
Results
The F21A mutation abolishes the growth-suppressive properties of PTEN In an attempt to determine the biological significance of the conserved amino acids 19-25 of PTEN, a point mutant, F21A, was generated ( Figure 1 ). We have established U87MG cell lines stably expressing either empty vector (pcDNA3), wild-type PTEN (PTEN-WT), the F21A PTEN mutant (PTEN-F21A) or catalytically inactive PTEN (PTEN-C124S). U87MG glioblastoma cells carry a frame-shift deletion in the PTEN gene and hence are PTEN-null at the protein level, making this cell line suitable for the study of PTEN function . Stable expression of wild-type PTEN in U87MG cells leads to a dramatic reduction in the growth of these cells, whereas expression of catalytically inactive PTEN-C124S does not affect the growth of U87MG cells (Furnari et al., 1997; Li and Sun, 1998) . We have examined the growth rate of the various U87MG cell lines and found that the growth rates of PTEN-WT and PTEN-C124S-expressing cells are consistent with previous findings (Figure 2b ) (Li and Sun, 1998) . Expression of PTEN-WT suppresses the growth of U87MG cells in comparison to cells transfected with empty vector, whereas expression of PTEN-C124S does not induce growth suppression. The growth rates of two different PTEN-F21A cell lines were similar to those of PTEN-C124S cells, suggesting that the F21A mutation abolishes the growth-suppressive properties of PTEN (Figure 2b ). Parental U87MG cells or those expressing PTEN-C124S grow into aggregates with an elongated appearance. These morphological patterns are associated with oncogenic transformation (Li and Sun, 1998) . Stable expression of wild-type PTEN in U87MG induces a flattened cell shape and non-refractile appearance (Li and Sun, 1998) . We have obtained similar results: empty vector or PTEN-C124S-expressing U87MG cells are elongated and refractile, whereas PTEN-WT-expressing cells are flat and adherent. PTEN-F21A cells, however, do not have a flattened cell shape, and are not as elongated, refractile and heavily aggregated as PTEN-C124S cells (Figure 2a ).
F21A mutation abolishes the ability of PTEN to downregulate PI3K/Akt signaling Expression of wild-type PTEN in U87MG cells antagonizes PI3K/Akt signaling (Li and Sun, 1998; Ramaswamy et al., 1999; Sun et al., 1999) . This effect is dependent upon the PIP 3 phosphatase activity of PTEN (Myers et al., 1998; Ramaswamy et al., 1999) . Loss of this function leads to upregulation of PI3K/Akt signaling and hence promotes enhanced proliferation, survival and increased protein synthesis. We have determined the effect of expressing the F21A mutant on PI3K/Akt Figure 1 Multiple sequence alignment of exon 1 (amino acids 1-26) of PTEN protein from diverse species. The lipid/PIP 2 binding motif (amino acids 6-15) is underlined, and the corresponding consensus sequence is shown below in parenthesis. The residues corresponding to the CLS (amino acids 19-25) are underlined, and amino acids required for cytoplasmic localization are shown in green. The germline/somatic mutations within this region are indicated by the arrows. (Figure 3b ). Not surprisingly, expression of the F21A mutant does not affect downstream target of rapamycin (TOR)-signaling. Whereas expression of wild-type PTEN downregulates the levels of phosphorylated p70-S6K and phosphorylated 4E-BP1, the F21A and C124S mutants have no effect on p70-S6K and 4E-BP1 phosphorylation (Figure 3c ). Consistent with the growth rate of these cells, p27 is only induced by expression of wild-type PTEN, but not by the F21A and C124S PTEN mutants ( Figure 3c ). As expected, treatment of these cells with LY294002, a PI3K inhibitor, also increases p27 levels, and downregulates the phosphorylation of p70-S6K and 4E-BP1. Furthermore, treatment of these cells with rapamycin, an mTORspecific inhibitor, also downregulates p70-S6K and 4E-BP1 phosphorylation. proteins were expressed in bacteria and purified with a Ni 2 þ -NTA-agarose slurry, and catalytic activity was assayed against water-soluble PtdIns (3,4,5)P 3 . The F21A mutant protein phosphatase activity is similar to that of wild-type PTEN protein, indicating that the F21A mutation does not affect the lipid phosphatase activity (Figure 4a ). The inability of the PTEN-F21A mutant protein to attenuate growth and downregulate PI3K/Akt signaling must, therefore, reflect impairment of a function distinct from lipid phosphatase activity.
F21A mutation localizes PTEN to the nucleus
The N-terminal PIP 2 binding motif of PTEN is required for the efficient localization to the plasma membrane (Das et al., 2003; Walker et al., 2004) . The PTEN-K13E somatic mutation identified in glioblastoma, which is located within the N-terminal PIP 2 binding motif, causes inefficient membrane targeting in vitro and in whole cells (Duerr et al., 1998; Walker et al., 2004) . PTEN-K13E retains wild-type lipid phosphatase activity in vitro, but fails to inhibit cell proliferation and to prevent Akt phosphorylation when expressed in U87MG cells. Membrane targeting of PTEN-K13E by insertion of a myristylation signal restores PTEN function in reconstituted U87MG cells. The biological consequences of the K13E mutation are similar to those caused by the F21A mutation, which retains wild-type lipid phosphatase activity in vitro, but has an impaired ability to attenuate cell growth. Because the F21A mutation is near the N-terminal PIP 2 binding motif (Figure 1 ), it appeared likely that this mutation also interferes with the targeting of PTEN to lipid membranes. In order to test the effects of the F21A mutation on PTEN localization, we generated C-terminal enhanced green fluorescence protein (EGFP)-tagged PTEN-WT, F21A and C124S. U87MG and HEK-293 cells were transiently transfected and examined 48 h post-transfection by fluorescence microscopy ( Figure 4b and c) and confocal microscopy (data not shown). PTEN-WT and PTEN-C124S show a diffuse cytoplasmic and nuclear localization consistent with previous observations (Figure 4b and c) (Furnari et al., 1997; Li and Sun, 1997; Das et al., 2003) . Surprisingly, the PTEN-F21A mutant localizes predominantly in the nucleus in both U87MG and HEK-293 cells (Figure 4b and c). Nuclear localization of PTEN-F21A was confirmed by 4 0 ,6-diamidino-2-phenylindole (DAPI) staining as shown by the overlay of the EGFP and DAPI images of the same group of cells (Figure 4b and c, bottom panel). In order to test for possible dominance of the F21A mutation, we examined the double-mutant, PTEN-F21A-C124S. The single-mutant PTEN-C124S localizes primarily in the cytoplasm, but the PTEN-F21A-C124S double mutant localizes in the nucleus, indicating that the aberrant nuclear localization induced by the F21A mutation is dominant and independent of PTEN phosphatase activity (Figure 4c ). We also examined the localization of EGFP-tagged PTEN-K13E, which has not been previously examined. This mutant localizes primarily to the cytoplasm, and in some cells this mutant is excluded from the nucleus (Figure 5a ). These data support the conclusion that the mechanisms of loss of growth suppressive functions for the K13E versus the F21A mutant are distinct. These results suggest that PTEN-K13E impairs membrane binding and recruitment, whereas PTEN-F21A is retained in the nucleus. These two distinct mechanisms for loss of tumor suppressor activity do not affect lipid phosphatase activity. 
Nuclear PTEN G Denning et al
Targeting of the F21A mutant to the plasma membrane restores its ability to downregulate Akt If nuclear localization prevents PTEN-F21A from regulating PI3K-Akt signaling, then targeting the mutant protein to the plasma membrane should restore the ability to downregulate Akt. Such localizationdependent restoration of function would also be consistent with the finding that the F21A mutant retains lipid phosphatase activity in vitro. The F21A mutant was targeted to the plasma membrane with an Nterminal myristylation signal, and this myristylated F21A protein was as effective as myristylated PTEN-WT in reducing the levels of phosphorylated Akt (Figure 4d ). This result also suggests that F21A can function as a lipid phosphatase in a cellular environment. Fluorescence microscopy of transiently transfected cells confirmed the localization of the myristylated F21A protein to the plasma membrane ( Figure 4e ). However, cell lines that stably express myristylated PTEN-WT or the myristylated F21A protein could not be established, presumably because of the strong growth-suppressive effect of PTEN that is constitutively localized to the plasma membrane.
Germline and somatic mutations surrounding F21A, but not the N-terminal PIP 2 binding motif, lead to nuclear localization of PTEN while retaining wild-type lipid phosphatase activity The F21A mutant has not been encountered as a spontaneous, naturally occurring mutation in PTEN, and its properties may be unique and without relevance to human disease. We, therefore, examined diseaserelated germline and somatic mutations surrounding the F21 site and compared them to mutations within the N-terminal PIP 2 binding motif (Table 1) . We determined the cellular localization and in vitro lipid phosphatase activity of mutants within the highly conserved amino acids 20-25 (GFDLDL), which include the germline mutation D24Y associated with the Bannayan-RileyRuvalcaba Syndrome (BRRS), and the somatic, cancerassociated mutations G20E, L23F, D24N and the D24/L25 deletion of PTEN expressed as EGFP or glutathione S-transferase (GST)-tagged fusion proteins.
PTEN-G20E, PTEN-L23F, PTEN-D24N (data not shown) and PTEN-D24Y localize primarily in the nucleus in HEK-293 cells (Figure 5a ), suggesting that this region of PTEN plays an important role in the maintenance of cytoplasmic localization. The PTEN deletion mutant, D24/L25, shows partial recovery of cytoplasmic localization (data not shown). On the other hand, somatic, cancer-associated mutants within the N-terminal PIP 2 binding motif (S10N, K13E, R15S and Y16C) show cytoplasmic localization when transiently expressed in HEK-293 cells (Figure 5a and data not shown). These observations suggest distinct control of PTEN localization by these juxtaposed regions (refer to Table 1 ).
We then determined lipid phosphatase activity of the germline and somatic mutations in the region defined by residues 20-25. GST-tagged PTEN mutant proteins were expressed and purified with glutathione sepharose 4B slurry, and catalytic activity was assayed against water-soluble PIP 3 . The majority of these N-terminal mutants retain lipid phosphatase activity in vitro comparable to that of wild-type PTEN ( Figure 5b and Table 1 ). These results suggest that loss of PTEN growth-suppressive activity in these mutants is not due to the loss of lipid phosphatase activity, but is probably related to nuclear localization. The analysis of these N-terminal mutants supports the conclusion that amino acids 20-25 of human PTEN are important determinants of cytoplasmic localization.
To further define the amino acids required for cellular compartmentalization of PTEN, alanine mutational scanning of this region was performed, and the results were compared with data from germline and somatic mutants. The alanine scanning mutants included Q17A, E18A, D19A, D22A, L25A and T26A (Table 2 ). The Q17A and E18A mutants exhibit cytoplasmic localization like the wild-type protein, but the D19A mutant is predominantly nuclear (data not shown, Table 2 ). Nuclear localization is also observed with the L25A mutant, whereas the T26A mutant is cytoplasmic (data not shown). The D22A mutant is primarily cytoplasmic, in contrast to the other mutants in this region (D19A, G20A, F21A, L23F), which are nuclear. Amino acid 22 may, therefore, not be essential for cytoplasmic Nuclear PTEN G Denning et al localization. The D22A mutant has, like the other mutants in this region, wild-type lipid phosphatase activity in vitro and, in contrast to nuclear PTEN, is able to reduce the levels of phosphorylated Akt in transient transfection (data not shown). These data confirm the important role of amino acids 19-25 in determining cellular localization of PTEN. Amino acids G20, F21, L23 and D24, in particular, are critical and cannot be mutated without loss of cytoplasmic localization.
Somatic PTEN mutants localized in the nucleus show loss of growth suppressive activity in U87MG cells
In order to assess the growth suppressive functions of naturally occurring PTEN mutants that localize to the nucleus, we have generated U87MG cell lines stably expressing cancer-associated mutants PTEN-G20E, L23F or D24N. These mutants not only exhibit strong nuclear localization (refer to Figure 5a , data not shown for D24N), but also retain wild-type lipid phosphatase activity. We examined phosphorylation status of Akt (Figure 6a ), proliferation rates ( Figure 6b ) and anchorage-dependent growth (Figure 6c and d) of these mutant-expressing cells. Consistent with our observations with the PTEN-F21A mutant, the G20E, L23F and D24N are unable to reduce phosphorylated levels of Akt (Figure 6a ). Furthermore, these mutations result in loss of the growth-suppressive properties of PTEN, with proliferation rates similar to empty vector or to PTEN-C124S-expressing cells (Figure 6b ). Colony formation in soft agar was determined to measure the anchorage-independent growth as a hallmark of transformed cells. Wild-type PTEN greatly reduces the ability of U87MG cells to grow in soft agar, whereas this effect is not seen with PTEN-C124S (Li and Sun, 1998) . We have used wild-type and the C124S mutant proteins as positive and negative controls (Figure 6c and d) . Cells expressing PTEN-F21A and PTEN-D24N form agar colonies with the same efficiency as cells expressing PTEN-C124S. Anchorage-independent growth of cells expressing the G20E and L23F mutants is reduced compared to vector control, but it is significantly above colony formation by PTEN-WT-expressing cells, and colony sizes are not significantly different from those of the vector control. These observations indicate that somatic mutations near the F21 residue, leading to nuclear localization, also induce a loss of growthinhibiting activity.
Discussion
Cellular compartmentalization regulates the function of many tumor suppressor proteins (Fabbro and Henderson, 2003) . PTEN can localize to the cytoplasm and to the nucleus, but little is known about the role of nuclear PTEN in tumor suppression (Lian and Di Cristofano, 2005) . We generated the PTEN-F21A mutation as part of an investigation of the highly conserved region consisting of residues 19-25 (DGFDLDL) of human PTEN. The PTEN-F21A mutant is representative of other mutations in this region and defines this short stretch of amino acids as a critical determinant of PTEN cellular localization and function. The PTEN-F21A mutant fails to suppress the growth of U87MG glioblastoma cells, and has lost the ability to downregulate the phosphorylation of Akt. In these two points, PTEN-F21A is similar to the loss of function mutant PTEN-C124S that lacks lipid phosphatase activity, the enzymatic function that mediates cellular growth control and tumor suppression. However, in contrast to PTEN-C124S, the PTEN-F21A mutant retains lipid phosphatase activity, but is localized in the nucleus. Nuclear localization is also seen with other germ line, somatic and alanine scanning mutants that map to this region: D19A, G20E, F21A, L23F, D24N, D24Y and L25A. Somatic mutations in the nearby PIP 2 -binding motif (K31E and R15S) and surrounding sequences (S10N and Y16C) do not alter the cytoplasmic localization of PTEN. The T26A mutation also retains cytoplasmic localization. Within the region of amino acids 19-25, only residue 22 can be mutated without affecting cytoplasmic localization. We propose to refer to this region as CLS without implying a specific mechanism of action.
The mechanism(s) determining the cellular localization of PTEN are not fully understood. A recent study describes a hypothetical NLS in PTEN that can mediate nuclear import by the MVP . A sequence that initiates possible export from the nucleus has not been identified. The conserved region encompassing amino acids 19-25 of PTEN could be considered a candidate nuclear export signal. It resembles a canonical nuclear export signal in that it contains closely spaced leucines and other hydrophobic amino acids (DGFDLDL). However, our tests with Leptomycin B suggest that if this sequence functions in nuclear export, CRM1/exportin would not be the major export receptor (see Supplementary information). Alternatively, amino acids 19-25 of PTEN could contain a cytoplasmic retention signal whose function is destroyed by most mutations in this region. The mechanism of such putative cytoplasmic retention also remains to be investigated, but mutations within this CLS clearly show that this region plays a crucial role in the nucleocytoplasmic shuttling of PTEN.
A change in cellular compartmentalization is likely to affect the function of PTEN. The mutations in the CLS that cause nuclear localization induce similar changes in characteristic activities of PTEN. These changes include an inability of the mutant protein to attenuate the transformed morphology and growth rates of U87MG cells. The ability of wild-type PTEN to reduce anchorage-independent growth is also abolished by mutations in the CLS, and so is interference with Akt signaling. All the previously identified cancer-derived somatic mutations in the CLS show loss of tumor suppressor function. These observations document a lack of growth suppressive activities that are correlated with nuclear localization of the protein. Yet in all these cases lipid phosphatase activity is retained in the mutant proteins. Re-directing the mutant protein to the plasma membrane with the help of a myristylation signal restores the Akt-regulatory activity that had been lost with nuclear localization. We hypothesize that nuclear PTEN that still retains lipid phosphatase activity is unable to carry out critical functions that are essential to its growth suppressive activity. Although we have observed this correlation of nuclear localization and loss of growth-controlling activity in PTEN-null U87MG cells, the data derived from germline and somatic mutations suggest that this connection between cellular compartmentalization and function of PTEN may have broader validity. Our observations and conclusions are in complete agreement with the work of Vazquez and co-workers on PTEN-membrane interactions . Recent studies have attempted to assign specific functions to nuclear PTEN. PTEN that is targeted to the nucleus by the addition of an N-terminal NLS was 
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found to inhibit the growth of PTEN-null U251MG glioblastoma cells and inactivated p70-S6K without downregulating Akt (Liu et al., 2005b) . These observations are in apparent contradiction to our findings with CLS mutants in U87MG cells. It is possible that this discrepancy is due to differences in the cell type or in the culture conditions. A factor of potential importance is p53, which is mutated in U251MG cells but wild-type in U87MG (Van Meir et al., 1994) . PTEN interacts with p53 and regulates p53 levels, but differences between wild-type and mutated p53 in these interactions have not been studied in detail (Mayo et al., 2002; Trotman and Pandolfi, 2003) . Cellular growth conditions are another possible cause of the divergent observations. In the studies cited above, the U251MG cells were serum starved, whereas in the present investigation, the U87MG cells were cultivated in 10% fetal bovine serum (FBS). Our preliminary observations on PTEN that is tagged with an N-terminal NLS suggest that a portion of that protein is retained in the cytoplasm, which could also explain the discrepant observations on cell growth. A different study assigns to nuclear PTEN the ability to downregulate cyclin D1 and to interfere with the activating phosphorylation of mitogen activated protein kinase in MCF7 breast cancer cells . However, in contrast to U87MG cells, MCF7 cells express wild-type PTEN, which could conceivably contribute to the observed effects. Substantial additional work is needed to resolve these conflicts and to clarify the functions of nuclear PTEN. While this paper was in revision, Gil et al. (2006) published an extensive study on nuclear-cytoplasmic distribution of PTEN. Their data suggest that sequences contiguous with the PIP 2 binding motif also mediate nuclear localization in the context of a truncated version of PTEN (amino acids 1-375). They assign a proapoptotic role to nuclear PTEN, in contradiction to previous observations that supported a proapoptotic role for cytoplasmic PTEN . Gil et al., hypothesize that PTEN exists in two conformations, NLS-masked (cytoplasmic) and NLS-unmasked (nuclear). These states are dictated by nuclear exclusion motifs within the PTP, C2 and C-terminal domains and a nuclear localization domain within the PIP 2 binding motif. In the context of this model, the CLS defines a region of PTEN that, like the C-terminal nuclear exclusion motif, induces strong nuclear localization when mutated, suggesting that such mutations might cause a switch to an NLS-unmasked conformation. Combined with our data, these studies position the N-terminus of PTEN (PIP 2 binding domain/nuclear localization domain and the adjacent CLS region) as a critical region that not only determines nucleocytoplasmic localization, but also binds to the plasma membrane.
In summary, we have defined residues 19-25 in PTEN as a CLS that is essential for cytoplasmic localization. Mutations in the CLS preserve lipid phosphatase activity and induce nuclear localization with a concomitant loss of growth-regulatory functions.
Materials and methods

Cloning and plasmid construction
An EcoRI fragment containing the full-length C-terminally HA-tagged human PTEN cDNA (obtained from F Furnari) was cloned into the pcDNA3 vector and used to generate wildtype PTEN, the phosphatase-inactive C124S mutation, the mutations S10N, K13E, R15S, Y16C, Q17A, E18A, D19A, G20E, F21A, F21A-C124S, D22A, L23F, D24N, D24Y, L25A, T26A and the D24/L25 deletion as either C-terminally HA-tagged or EGFP-tagged constructs. The myristylation signal MGSSLSLPLSR was inserted into pcDNA3-PTEN-WT-EGFP, F21A and C124S plasmids. His 6 -tagged wild-type PTEN and C124S expression vectors were kindly provided by Drs Taylor and Dixon (University of California, San Diego, CA, USA). GST-tagged PTEN (pGEX-PTEN) plasmids were generated as described previously (Myers et al., 1997) . PTEN mutations were generated by site-directed mutagenesis. All plasmid vectors were verified by DNA sequencing.
Cell culture, stable cell lines and transfection HEK-293 and U87MG cells were maintained in high glucose Dulbecco's modified Eagle's medium (DMEM), with L-glutamine, 10% FBS and 5% penicillin-streptomycin. Stably transfected U87MG clones were generated by selection in 800 mg/ml of G418 sulfate. Transfections were performed using Lipofectamine.
Soft-agar assay for colony formation Agar colony formation was performed in DMEM containing 10% FBS, 500 mg/ml of G418 sulfate and 0.35% low melting agarose layered onto a base of DMEM, 10% FBS, 500 mg/ml of G418 sulfate and 0.7% agarose. Assays were run in triplicate and visualized by staining with crystal violet.
HA-Akt and Myr-PTEN-EGFP co-transfection
The effects of myristylated PTEN on Akt phosphorylation were examined in U87MG cells transiently co-transfected with the EGFP-tagged pcDNA3-Myr-PTEN expression plasmids and the pCDNA3-HA-Akt plasmid. Twenty-four hours posttransfection, cells were lysed in 1 Â radioimmunoprecipitation assay buffer supplemented with 0.1% sodium dodecyl sulfate (SDS), 20 mM b-glycerophosphate, 50 mM NaF, 1 mM benzamidine, and ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor cocktail, incubated with 1:150 dilution of HA.11 antibody. Antigen-antibody complexes were captured with protein G agarose. Immunoblot analysis was performed as described below.
Growth of U87MG-PTEN cell lines U87MG-PTEN clones were plated (5 Â 10 4 cells) onto 35 mm dishes. At the indicated time points, triplicate wells were trypsinized and counted or measured by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reaction.
Immunoblot analysis
Lysis of cells for immunoblot analysis was performed in NP-40 buffer (20 mM TRIS pH 7.4, 150 mM NaCl, 1 mM MgCl 2 , 1% NP-40 and 10% glycerol), supplemented with 1 mM DTT, 1 mM phenylmethylsulfonyl (PMSF), 50 mM b-glycerophosphate, 50 mM NaF and 1 Â protease Inhibitor cocktail. Lysates were clarified by centrifugation at 13 000 r.p.m. for 10 min at 41C, and the protein concentration was determined. Immunoblot analysis was by electrophoresis using either 4-20% Tris-glycine gels or 3-8% Tris-acetate gels. Proteins were electroblotted to polyvinylidene difluoride membranes.
Immunoblot analysis with HA.11, and antibodies against Akt, phospho-Akt (Ser473), p70-S6K, phospho-p70-S6K (Thr389), 4E-binding protein 1, phospho-4E-BP1 (Ser65), p27 and a-tubulin was performed at 1:1000 antibody dilution. Membranes were blocked in 5% non-fat dry milk in PBS containing 0.05% Tween 20 (PBST) for 1 h at RT and incubated with primary antibody in 5% bovine serum albumin (BSA) in PBST overnight at 41C. Membranes were washed three times in PBST and incubated in a 1:10 000 dilution of peroxidase-conjugated goat anti-mouse or anti-rabbit IgG (H þ L) in 5% non-fat dry milk in PBST for 1 h at RT. After washing twice with PBST and once with PBS, antigenantibody complexes were detected by chemiluminescence.
PDGF stimulation was performed by treating serumdeprived cells with 30 ng/ml of PDGF for 15 min. For LY294002 and rapamycin treatment, proliferating cells were treated with 20 mM LY294002 for 24 h or 20 nM rapamycin for 3 h. Control cells were treated with dimethyl sulfoxide (DMSO). Lysis and immunoblot analysis was as described above.
EGFP fluorescence microscopy
Transiently transfected cells plated onto eight-well collagen-coated slides were washed with PBS, fixed in Pipes, Hepes, EGTA, DMSO (PHEMO) buffer (68 mM piperazine-N,N 0 -bis(2-ethanesulfonic acid), 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 15 mM ethylene glycol bis(b-aminoethylether)-N,N,N 0 ,N 0 ,-tetraacetic acid 3 mM MgCl 2 Á 6H 2 O, 10% DMSO, 3.7% formaldehyde, 0.05% glutaraldehyde and 0.5% Triton X-100) for 10 min, and washed in PBS. Cells were mounted with DAPI and visualized by fluorescence microscopy.
PTEN-His 6 , PTEN-GST expression and purification His 6 -fusion proteins were expressed and purified from cultures of E. coli grown in Â 2 YT medium with 100 mg/ml ampicillin and 34 mg/ml chloramphenicol at 371C to A 600 0.6. Protein expression was induced with 0.4 mM isopropyl-b-D-thiogalactoside (IPTG) overnight at RT. Bacteria were resuspended in lysis buffer (50 mM Tris pH 8.0, 300 mM NaCl, 20 mM imidazole pH 8.0, 0.05% 2-b-mercaptoethanol, 0.5% Triton X-100, EDTA-free protease inhibitor). After sonication on ice, the lysate was clarified, and the supernatant was incubated with Ni 2 þ -NTA-agarose slurry for 2 h at 41C. The slurry was then washed five times with lysis buffer and twice in lysis buffer without detergent. Fusion proteins were eluted in lysis buffer without detergent containing 300 mM imidazole (pH 8.0). EDTA, dithiothreitol (DTT) and glycerol were added to final concentration of 2 mM, 2 mM and 25% (v/v).
GST-tagged fusion proteins were expressed and purified from cultures of DH5a cells grown in Luria-Bertini (LB) broth with 100 mg/ml ampicillin, which were diluted 1:200 in Â 2 YT medium containing 100 mg/ml of ampicillin and grown at 371C to A 600 0.8. Protein expression was induced with 0.1 mM IPTG for 48 h at RT. Bacteria were then harvested and suspended in ice-cold PBS/propidium iodide (PI)/dithiothreitol (DTT) solution (PBS containing 10 mM DTT, 200 mM PMSF, 1 mg/ml Pepstatin A and 50 mM Leupeptin). After sonication, Triton X-100 was added to the lysate to a concentration of 1% and incubated at RT for 1 h and at 41C for 1 h. The lysate was clarified and incubated overnight at 41C with glutathione sepharose. The slurry was washed three times with ice-cold PBS/PI/DTT, and GST-fusion proteins were eluted in 50 mM Tris-HCL pH 8.0, 10 mM reduced glutathione. Eluted protein was dialysed overnight in 100 mM Tris-HCL pH 8.0/ 10 mM DTT solution, and the dialysed protein was stored in 10% glycerol, 200 mM PMSF, 1 mg/ml Pepstatin A and 50 mM Leupeptin at À801C.
Phosphatase assay PTEN phosphatase activity was measured against water-soluble D-myo-PtdIns(3,4,5)P 3 as a substrate, using the malachite green phosphatase assay. Enzyme reactions were performed using 1 mg of protein and 70 mM D-myo-PtdIns(3,4,5)P 3 for 1 h for His 6 -tagged proteins or 40 min for GST-tagged proteins at 371C followed by color development for 15 min at RT. The amount (pmol) of free phosphate released by each enzyme reaction was determined by linear regression analysis against a phosphate standard curve.
